AU2021403025A1 - Method of treating progressive heart failure in subjects with class ii heart failure - Google Patents
Method of treating progressive heart failure in subjects with class ii heart failure Download PDFInfo
- Publication number
- AU2021403025A1 AU2021403025A1 AU2021403025A AU2021403025A AU2021403025A1 AU 2021403025 A1 AU2021403025 A1 AU 2021403025A1 AU 2021403025 A AU2021403025 A AU 2021403025A AU 2021403025 A AU2021403025 A AU 2021403025A AU 2021403025 A1 AU2021403025 A1 AU 2021403025A1
- Authority
- AU
- Australia
- Prior art keywords
- subject
- cells
- heart failure
- level
- class
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
- A61K38/385—Serum albumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Developmental Biology & Embryology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2020904675A AU2020904675A0 (en) | 2020-12-15 | Method of treating progressive heart failure in subjects with Class II heart failure | |
| AU2020904675 | 2020-12-15 | ||
| AU2021900059 | 2021-01-12 | ||
| AU2021900059A AU2021900059A0 (en) | 2021-01-12 | Method of treating progressive heart failure in subjects with Class II heart failure | |
| AU2021902941 | 2021-09-10 | ||
| AU2021902941A AU2021902941A0 (en) | 2021-09-10 | Method of treating progressive heart failure in subjects with Class II heart failure | |
| AU2021903365A AU2021903365A0 (en) | 2021-10-20 | Method of treating progressive heart failure in subjects with Class II heart failure | |
| AU2021903365 | 2021-10-20 | ||
| US202163289868P | 2021-12-15 | 2021-12-15 | |
| PCT/US2021/063645 WO2022132986A2 (en) | 2020-12-15 | 2021-12-15 | Method of treating progressive heart failure in subjects with class ii heart failure |
| US63/289,868 | 2021-12-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2021403025A1 true AU2021403025A1 (en) | 2023-07-20 |
Family
ID=79686821
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021403025A Pending AU2021403025A1 (en) | 2020-12-15 | 2021-12-15 | Method of treating progressive heart failure in subjects with class ii heart failure |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240041934A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024500698A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230119676A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021403025A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3202153A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022132986A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012048093A2 (en) | 2010-10-08 | 2012-04-12 | Osiris Therapeutics, Inc. | Enhanced msc preparations |
| WO2019102268A1 (en) | 2017-11-22 | 2019-05-31 | Mesoblast International Sarl | Cellular compositions and methods of treatment i |
| US12702683B2 (en) | 2019-01-03 | 2026-08-11 | Mesoblast International Sárl | Method for improving visual acuity |
| WO2021176001A1 (en) | 2020-03-05 | 2021-09-10 | Mesoblast International Sàrl | Method for treating inflammatory lung diseases using mesenchymal lineage precursor or stem cells |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5486359A (en) | 1990-11-16 | 1996-01-23 | Osiris Therapeutics, Inc. | Human mesenchymal stem cells |
| US6251295B1 (en) | 1998-01-08 | 2001-06-26 | Nexell Therapeutics Inc. | Method for recirculation washing of blood cells |
| US9205112B2 (en) * | 2007-04-23 | 2015-12-08 | Creative Medical Health, Inc. | Combination treatment of cardiovascular disease |
| CN107206027A (zh) * | 2014-12-23 | 2017-09-26 | 迈索布拉斯特国际有限公司 | 进行性心力衰竭的预防 |
| US20190224240A1 (en) * | 2016-01-11 | 2019-07-25 | Cardiocell, Llc | Cell therapy for the treatment of non-ischemic heart failure |
-
2021
- 2021-12-15 WO PCT/US2021/063645 patent/WO2022132986A2/en not_active Ceased
- 2021-12-15 AU AU2021403025A patent/AU2021403025A1/en active Pending
- 2021-12-15 CA CA3202153A patent/CA3202153A1/en active Pending
- 2021-12-15 JP JP2023536167A patent/JP2024500698A/ja active Pending
- 2021-12-15 KR KR1020237023192A patent/KR20230119676A/ko active Pending
- 2021-12-15 US US18/257,515 patent/US20240041934A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022132986A2 (en) | 2022-06-23 |
| KR20230119676A (ko) | 2023-08-16 |
| WO2022132986A3 (en) | 2022-07-28 |
| US20240041934A1 (en) | 2024-02-08 |
| CA3202153A1 (en) | 2022-06-23 |
| JP2024500698A (ja) | 2024-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240041934A1 (en) | Method of treating progressive heart failure in subjects with class ii heart failure | |
| US20240197787A1 (en) | Method for treating acute respiratory distress syndrome (ards) in specific patients using mesenchymal lineage precursor or stem cells | |
| US20230165904A1 (en) | Method for treating hyperinflammation using mesenchymal lineage precursor or stem cells | |
| CA3168330A1 (en) | Method for treating chronic graft versus host disease | |
| US20250032552A1 (en) | Method of treating severe graft versus host disease | |
| US20230293589A1 (en) | Method for treating inflammatory lung diseases using mesenchymal lineage precursor or stem cells | |
| US20250090589A1 (en) | Method of treating progressive heart failure in subjects at high risk of poor outcomes | |
| JP2025540289A (ja) | 持続性炎症を有する対象における心不全の治療方法 | |
| EP4264275A2 (en) | Method of treating progressive heart failure in subjects with class ii heart failure | |
| EP4433070A1 (en) | Method of treating progressive heart failure in subjects at high risk of poor outcomes | |
| CN116829162A (zh) | 治疗患有ii级心力衰竭的受试者的进行性心力衰竭的方法 | |
| AU2024332651A1 (en) | Third line treatment for gvhd |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ METHOD OF TREATING PROGRESSIVE HEART FAILURE IN SUBJECTS WITH CLASS II HEART FAILURE |
|
| HB | Alteration of name in register |
Owner name: MESOBLAST INTERNATIONAL SARL Free format text: FORMER NAME(S): MESOBLAST INTERNATIONAL SARL |